Identifying the radioresponsive genome for genomics-guided radiotherapy
Menée à partir du séquençage ciblé du génome d'échantillons tumoraux issus de 20 107 patients atteints d'un cancer de stade avancé, cette étude met en évidence une association entre l'inactivation somatique d'ATM et une meilleure efficacité de la radiothérapie
Nearly 20 years ago sequencing of the human genome heralded 21st centuryprecision medicine that harnessed the power of genetic profiling to personalize cancer treatments. While much effort is put into targeted sequencing to identify druggable targets for advanced cancers, consideration of predicting tumor benefit from radiation lags behind.A paper in this issue of JNCIprovidesthe impetus to progress genetic profiling to guide the useof radiotherapy.
Journal of the National Cancer Institute , éditorial en libre accès, 2019